Kornimate/medical-research-clean huggingface dataset:
immunotherapy-related crp kinetics in metastatic gynecological malignancies

Conditions: Gynecological Malignancies; Cervical Cancer; Endometrial Cancer; Ovarian Cancer; Vulvar Cancer

Summary: ick-gyn is a prospective, multicentric, non-interventional investigator-initiated trial (iit) that aims to investigate the prognostic value of crp kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ici) therapy on the objective response rate (orr), progression-free survival (pfs) and overall survival (os).

immunotherapy, which involves activating the body's immune system for cancer treatment, has already been widely incorporated into the standard care of patients with advanced and metastatic gynecological cancers. this study aims to investigate how inflammatory markers such as c-reactive protein (crp) change during and after immunotherapy. study findings from other tumor types (kidney, lung, bladder) suggest that immunotherapy is particularly effective when a mild inflammatory response is triggered in the body. the investigators want to examine this using crp measurement. crp measurement can easily be integrated into clinical routine as it only requires a blood sample. the goal of this prospective study is to determine whether changes in crp levels in the blood can predict the disease progression or response to immunotherapy.

Eligibility criteria:
inclusion criteria: * women ≥ 18 years of age * histologically proven metastatic gynecological malignancies irrespective of therapy line * patients with advanced or metastatic gynecological malignancies must fulfill treatment requirements for ici therapy in the experimental group * planned ici therapy in combination with palliative chemotherapy in the experimental group * patients with advanced or metastatic gynecological malignancies that undergo chemotherapy without icis in the first therapy line in the control group * written informed consent into ick-gyn exclusion criteria: * missing indication for ici therapy in the experimental group * any ici therapy before inclusion into the trial * patients with advanced or metastatic endometrial or cervical cancer in the second or higher therapy line without indication to ici therapy * pregnant or lactating patients * inadequate general condition (not fit for chemotherapy)
self-collection for cervical cancer screening and hpv vaccination for cancer prevention among women in emergency care in northeast florida

Conditions: Human Papillomavirus-Related Cervical Carcinoma

Summary: human papilloma virus (hpv) is a cause of cervical cancer in women. this study is being done to identify sites for cervical cancer screening and education regarding hpv vaccination outside of the traditional settings of primary care and gynecologic clinics. identifying non-traditional cancer screening settings may increase cancer screening completion and hpv vaccination among women with limited health care knowledge and access who are vulnerable to health disparities.


Eligibility criteria:
inclusion criteria: * adults assigned as female at birth age 18-65 with a mayo clinic medical record number exclusion criteria: * adults assigned as female at birth age 0-17 * adults assigned as female at birth age \> 65 * adults assigned as male at birth * adults assigned as female at birth without a mayo clinic medical record number
to identify urinary biomarkers associated with gestational diabetes mellitus [gdm]

Conditions: Gestational Diabetes

Summary: gestational diabetes mellitus(gdm) is one of the most common complications of pregnancy. the incidence of gdm is higher in asian than in other regions, and gdm can increase the risk of a series of perinatal complications. the investigators has been committed to the early diagnosis of gdm, and several biomarkers in the first trimester and urinary proteomic markers that were associated with gdm have been found. based on the previous work, the aim of this study was to verify the predictive ability of urinary proteomic markers for gdm that has been found in the previous study of the researchers. this study is a multi-center, prospective, and observational study. urine samples will be collected twice, at 12 weeks and 24-28 weeks of gestation, respectively.

the eligibility criteria are as follows: 1. singleton pregnant women over 18 years old; 2. gestational age less than 12 weeks; 3. regular follow-up until delivery; 4. able to understand and sign an informed consent. the exclusion criteria of pregnant women are as follows: 1. with impaired glucose tolerance or diabetes mellitus before pregnancy; 2. severe chronic diseases or infectious diseases (e.g., liver disease, urinary system disease, cardiovascular disease, autoimmune disease, hematological disease, aids and other diseases before pregnancy); 3. medications other than vitamins used during pregnancy; 4. inability to understand and follow-up regularly; 5. other conditions judged by the investigators to be inappropriate for participation in the study.

Eligibility criteria:
inclusion criteria: * women of childbearing age who are in early pregnancy(gestational age less than 12 weeks); * regular prenatal examination until delivery; * older than 18 years old; * obtained informed consent from participants and/or their family members. exclusion criteria: * twins or multiple pregnancy; * with impaired glucose tolerance or diabetes mellitus before pregnancy; * with severe chronic diseases or infectious diseases (e.g., liver disease, urinary system disease, cardiovascular disease, autoimmune disease, hematological disease, aids and other diseases before pregnancy); * medications other than vitamins used during pregnancy; * inability to understand and follow-up regularly; * other conditions that were judged by the investigator to be ineligible for participation in the study.

Keywords: gestational diabetes urinary proteomics early prediction
a gender-specific posterior cruciate-substituting high-flexion knee prosthesis does not improve fit and function

Conditions: Osteoarthritis of the Knee; Female

Summary: the purpose of this study was to compare functional and radiographic results, range of motion of the knee, patient satisfaction, femoral component, revision and complication rates in patients receiving either a standard posterior cruciate substituting-flex (lps-flex) or gender-specific posterior cruciate substituting-flex (lps-flex) total knee prosthesis.

recently much debate and discussion has focused on the effect of gender-specific total knee arthroplasty. the purpose of this study was to compare functional and radiographic results, range of motion of the knee, patient satisfaction, femoral component, revision and complication rates in patients receiving either a standard posterior cruciate substituting-flex (lps-flex) or gender-specific posterior cruciate substituting-flex (lps-flex) total knee prosthesis.

Eligibility criteria:
inclusion criteria: * end-stage osteoarthritis of the knee joint requiring total knee arthroplasty with bilateral disease, in female patients exclusion criteria: * male patient * inflammatory disease * patient with other lower extremity disease which may affect functional outcome * neurologic disease effecting patients lower extremity * revision surgery

Keywords: gender specific knee osteoarthritis total knee arthroplasty
endoscopic ultrasound-guided celiac plexus neurolysis (eus-cpn) for chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: physicians need a tracking system for specific treatment modalities, and data to determine the impact of endoscopic ultrasound pain management for patients with chronic pancreatitis.

chronic pancreatitis is extremely painful and pain management in patients with chronic pancreatitis is challenging. the etiology of abdominal pain in chronic pancreatitis is considered multifactorial. current treatments for pain control primarily include narcotic \& opioid administration; however, these medications require titration of dosage for optimal pain control and are frequently followed by adverse effects such as constipation, nausea or drug addiction. currently, the fda has imposed strict regulations regarding the amount, frequency \& length of time patients may receive these medications. with tightly controlled regulations for prescribing narcotics and opioids for chronic pain management, the epidemic of street drug usage and overdose has dramatically increased. alternatively, celiac plexus block and celiac plexus neurolysis performed under eus guidance have been employed for pain control for at least 2 decades and deemed safe. celiac plexus block refers to temporary inhibition of nerves of the celiac plexus, by using a combination of steroid and numbing medications injected into the celiac plexus ganglia. celiac plexus neurolysis (cpn) refers to a temporary to semi-permanent inhibition of nerves of the celiac plexus ganglia. injection of alcohol as a neurolytic agent is used in place of the steroid which causes neurolysis of the celiac plexus or ganglia. this study will focus on collecting data related to endoscopic ultrasound procedures performed by indiana university eus physicians; specifically for the management of chronic pancreatitis pain. this data will be used for research purposes to determine the clinical impact of eus-cpn management in chronic pancreatitis pain. the physicians will also be able to better understand the patient's condition and disease process that may lead to improved patient management.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * referral for the treatment of pain related to chronic pancreatitis exclusion criteria: * less than 18 years of age * absence of chronic pancreatitis

Keywords: pancreatitis indiana block celiac plexus
poasac study (preoperative anemia severity and classification study)

Conditions: Anemia

Summary: the goal of this observational study focuses on the effect of different preoperative anemia status on perioperative complications in patients under moderate- to high-risk surgery. different anemia types conclude iron-deficiency anemia(ida), anemia of chronic disease/anemia of inflammation(acd/ai), and combined anemia.the main question it aims to answer is whether there is a difference in the incidence of complication related to oxygen supply and demand imbalance in patients with ida, acd/ai or combined anemia. patients without preoperative anemia will be recruited as the control group for secondary outcome analysis, which is whether there is a difference in the incidence of complication related to oxygen supply and demand imbalance in patients with or without anemia.

the investigators aim to screen patients according to including and excluding criteria. according to the hemoglobin level, if the patient is anemia, the investigators will offer some lab tests for serum iron, transferrin saturation, c-reactive protein to classify different anemia status. besides, the investigators will include patients without anemia in a 2:1 ration of anemia to non-anemia. the perioperative assessment and follow-up are the same for all the included patients.

Eligibility criteria:
inclusion criteria: * age 18 years or older * scheduled for elective moderate- to high-risk surgery other than intracranial and cardiac surgery * predicted surgery time longer than 1 hour and hospital stay longer than 24 hours * understand and agree to participate exclusion criteria: * pregnant * live at areas higher than 2,500 meters above sea level * with hematological diseases other than anemia * with severe comorbidities that might interfere outcome assessment, like uremia, dementia, and so on * can't cooperate or communicate, or reject to sign informed consent form
operant h-reflex down-conditioning of rectus femoris in post-stroke stiff knee gait

Conditions: Training

Summary: the investigators performed a feasibility trial of operant conditioning of spinal reflex excitability on five healthy individuals and two post-stroke individuals. the investigators found that operant conditioning of rectus femoris reflex excitability was feasible in all participants.

the investigators performed a cohort study on 7 individuals (5 healthy, 2 post-stroke) to examine the feasibility of operant down-conditioning of rectus femoris reflex excitability (i.e. h-reflex). each individual performed 30 sessions, 6 baseline sessions with no operant conditioning (225 trials of surface electrical stimulation of the femoral nerve), followed by 24 training sessions (20 baseline trials followed by 225 trials with feedback of h-reflex magnitude). the investigators' main outcome measure was rectus femoris h-reflex magnitude. we also examined h-reflex magnitude of other quadriceps muscles.

Eligibility criteria:
inclusion criteria: * premorbidly independent * mild to moderate impairment determined by standard practices per the physical therapist * ability to stand for 10-minute intervals unassisted * ability to walk for 10-minutes on a treadmill * reduced knee flexion during phase and skg as determined by a clinician * hemiparesis * ability to provide informed consent exclusion criteria: * history of cerebellar stroke, multiple stroke * history of serious lower limb musculoskeletal injury * functionally relevant osteoarthritis and weight-bearing restrictions * have condition related to claustrophobia or other mri contraindications * functionally relevant cognitive impairment * functionally relevant vision impairment * took antispasmodic medication one day prior to the session * had botox injection one week prior to the session * pregnant women
multiple arm study of sebacia microparticles in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: prospective, multicenter study with multiple arms to examine the safety and effectiveness of the sebacia acne treatment system for the treatment of acne vulgaris.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe acne vulgaris exclusion criteria: * use of oral retinoid therapy in the past 12 months * pregnancy, lactating, or planning to become pregnant * excessive scarring in the treatment area, or other condition that would impact the ability to evaluate acne
effect of astaxanthin on the patients with alzheimer disease

Conditions: To Evaluate the Possible Benefit of Astaxanthin on Alzheimer Disease

Summary: this study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of astaxanthin on alzheimer disease. the enrolled alzheimer patients will take astaxanthin or placebo for 1 year. we will follow up mini-mental state examination, cognitive ability screening instrument, clinical dementia rating, and neuropsychiatric inventory at the end of the study.

this study aims to examine the benefit of astaxanthin as adjuvant therapy for alzheimer's disease.

Eligibility criteria:
inclusion criteria: 1. 60 ≦ age ≦ 90 2. clinical dementia rating scale = 0.5 or 1 3. under treatment with donepezil、rivastigmine or galantamine with good medical adherence 4. get a signed informed consent from the patient or his/her family exclusion criteria: 1. not using or poor medical adherence to donepezil、rivastigmine or galantamine 2. combined using memantine or other cerebral perfusion enhancing agent, such as piracetam, dihydroergotoxine, nicergoline etc. 3. new cerebrovascular disease happens during 3-year follow up 4. mixed type dementia 5. major psychiatric disease (such as depression, bipolar disorder, schizophrenia) or substance abuser (such as alcohol, illegal drug, hypnotics) 6. heart failure, end stage renal disease, liver cirrhosis, or other major organ failure 7. severe hearing impairment results in incomplete survey of neuropsychatric evaluation 8. no informed consent or no regular follow up

Keywords: alzheimer disease astaxanthin
doppler ultrasound for prediction of reversibility of acute kidney injury in septic icu patients

Conditions: Acute Kidney Injury; Sepsis; Renal Resistive Index

Summary: purpose: the aim of this study was to assess the ability of early discrimination between transient and persistent acute kidney injury (aki) using the color doppler ultrasound derived renal resistive index (ri) and semi-quantitative evaluation of intra-renal vascularization in septic patients in an intensive care unit (icu). methods: prospective observational cohort study with unselected, with 32 adult consecutive septic patients. patients were divided into 3 groups: group 1: patients without progression to aki, group 2: transient aki, group 3: persistent aki.

purpose: the aim of this study was to assess the ability of early discrimination between transient and persistent aki using the color doppler ultrasound derived renal resistive index (ri) and semi-quantitative evaluation of intra-renal vascularization in septic patients in an intensive care unit (icu). additionally, the investigators aimed to identify whether these indexes are early predictors of the prognosis of renal function in this group of patients. and compare the diagnostic accuracy of those and other renal indexes for the identification of aki reversibility. methods: this was a prospective observational cohort study with unselected, consecutive septic patients included. thirty-two adult septic patients hospitalized in a general icu were studied. after the determination of sepsis, patients were divided into 3 groups: group 1 included patients without progression to aki, group 2 included patients with transient aki and group 3 patients with persistent aki.

Eligibility criteria:
inclusion criteria: * septic patients in icu * age 18 years or older exclusion criteria: * icu stay less than 3 days

Keywords: icu renal resistive index acute kidney injury sepsis
cognitive stimulation in adolescents

Conditions: Substance Use Disorders

Summary: the purpose of this study is to see if computer tasks that challenge the brain (cognitively stimulating tasks) can improve memory and other types of thinking in adolescents and young adults who are being treated for substance use problems. the study will compare the effects of different versions of the computer tasks.


Eligibility criteria:
inclusion criteria: * age 14-21 * diagnosis of substance use disorder (sud) by dsm-iv criteria with marijuana as primary substance of abuse * eligible for intensive outpatient treatment exclusion criteria: * untreated psychiatric disorder that might make participation hazardous * any condition associated with severe cognitive impairment
stress response pathways in vitiligo

Conditions: Vitiligo

Summary: the purpose of this study is to investigate stress response pathways in tissues and melanocytes from patients with vitiligo. investigators are collecting evidence of upr and stress response activation in tissues and melanocytes from patients with vitiligo. individuals with vitiligo will have punch biopsies to study stress response upr activation and nf-κb signaling to test our hypothesis. in order to characterize differences between disease and normal states, a second arm of control individuals (arm 2) will be recruited.

identifying a role for nf-κb signaling in vitiligo may improve therapies for this disfiguring disorder. current treatments vary in effectiveness and may not always be long lasting cases. the nf-κb pathway and il-6 itself are the target of several fda approved drugs, thus opening new therapeutic avenues.

Eligibility criteria:
inclusion criteria: * to be eligible for participation, subjects must meet all of the following criteria: * must have a clinical exam consistent with and diagnosis of non-segmental vitiligo * must be normally pigmented * no clinical presentation of vitiligo exclusion criteria: * outside of the specified age range * no clinical diagnosis of vitiligo * use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineurin inhibitors and/ or vitamin d analogs within 4 weeks of enrollment * use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment * history of keloids or hypertrophic scars * patients with pacemakers or defibrillators or heart valves * patients on plavix, warfarin or similar anticoagulation medicine * pregnant females * lactating women * allergies or sensitivity to lidocaine or epinephrine * outside of the specified age range * abnormally pigmented at potential biopsy sites (non-vitiligo) * clinical presentation of vitiligo * use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineuron inhibitors and/ or vitamin d analogs within 4 weeks of enrollment * use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment * history of keloids or hypertrophic scars
osa and sudden sensorineural hearing loss

Conditions: Obstructive Sleep Apnea; Sudden Hearing Loss

Summary: this study studies the prevalence between obstructive sleep apnea syndrome and sensorineural hearing loss. we recruit patients who have been treated for sudden sensorineural hearing loss in poitiers' university hospital between 2010 et 2017, and we detect if they have osa with a ventilatory polygraphy.


Eligibility criteria:
inclusion criteria: * past medical history of sudden hearing loss between 2010 and 2017 * no contraindication to a non supervised sleeping monitoring exclusion criteria: * past medical history of fluctuant hearing loss or pre-existant significative hearing loss
glaucoma screening with smartphone ophthalmology

Conditions: Glaucoma

Summary: the purpose of this study is to assess the accuracy and reliability of smartphone ophthalmoscopy compared to slit-lamp biomicroscopy in glaucoma screening for potential community screening programs.


Eligibility criteria:
inclusion criteria: * ocular hypertension * glaucoma exclusion criteria: * substantial media opacity * refractive error outside the range from -10.00 to +5.00 diopters
european observational study of enzalutamide in metastatic castration resistant prostate cancer (mcrpc)

Conditions: Metastatic Castration Resistant Prostate Cancer

Summary: the purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mcrpc) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.


Eligibility criteria:
inclusion criteria: * men with mcrpc who have been prescribed enzalutamide as part of standard clinical practice * germany only: enzalutamide will be prescribed according to the current smpc (summary of product characteristics) exclusion criteria: * patients with the following will be excluded from study participation in france only: * patients who have previously been treated with abiraterone acetate (zytiga®) after docetaxel chemotherapy. * patients who have previously been treated with cabazitaxel (jevtana®) * patients who have previously been treated with xtandi® * patients taking part in an interventional clinical trial

Keywords: xtandi enzalutamide prostate cancer metastatic castration resistant prostate cancer